{"id":135993,"date":"2026-09-25T02:07:38","date_gmt":"2026-09-25T02:07:38","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/135993\/"},"modified":"2026-09-25T02:07:38","modified_gmt":"2026-09-25T02:07:38","slug":"hsbc-lifts-novartis-downgrades-amgen-in-biopharma-catalyst-review","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/135993\/","title":{"rendered":"HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Investing.com &#8212; HSBC adjusted ratings and target prices across its biopharma coverage, citing &#8220;a lower sector additional risk premium&#8221; following a rally in the second quarter of 2026.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Analysts led by Rajesh Kumar said pharma multiples are at a decade high, and further outperformance will require a medium-term growth upgrade rather than &#8220;defensive positioning in out of AI\/Tech rotation.&#8221; The team mapped and scored more than 100 clinical catalysts through 2027 across its coverage universe.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;The next 12 months look less like &#8216;a rising tide lifts all boats&#8217; and more like bottom-up stock picking,&#8221; the analysts wrote, adding that catalyst quality, franchise adjacency, and loss-of-exclusivity operational gearing will separate winners from value traps.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">HSBC upgraded Novartis to Hold from Reduce, raising its target price to 110 Swiss francs from 95, after &#8220;back-to-back trial failures for pelacarsen and del-desiran.&#8221; The analysts said they expect a near-term consensus downgrade cycle, but believe &#8220;the negative catalyst path has largely played out,&#8221; with investor focus shifting to the upcoming RECHARGE trial readout.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Amgen was downgraded to Hold from Buy, with the target price cut to $425 from $445. HSBC said the stock has &#8220;re-rated on strong operational execution and positive estimate revisions&#8221; and now trades close to its target price, leaving &#8220;near-term upside as more limited.&#8221; The analysts flagged that the company&#8217;s re-rating over the next 12 months will hinge on the MariTide obesity trial readout, an area they described as &#8220;an increasingly crowded space.&#8221;  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The broker also retained its Buy rating on AbbVie and raised its target price to $315 from $300. The analysts said pipeline readouts for Skyrizi and Rinvoq could let management raise peak sales guidance in early 2027, potentially shifting 2027-31 growth rates &#8220;from low mid-single digit to high mid-single digit.&#8221;  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Bayer also kept its Buy rating, with the target price lifted to \u20ac65 from \u20ac60. HSBC pointed to a &#8220;favourable judgement from the US Supreme Court&#8221; on glyphosate litigation and said a September 2026 class-action resolution &#8220;could be a meaningful re-rating driver,&#8221; potentially freeing capital for pipeline reinvestment.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">HSBC&#8217;s preferred stocks include Buy-rated AbbVie, Johnson &amp; Johnson, Merck, Bayer and Sanofi, while Reduce-rated Eli Lilly was named the least preferred name in the coverage group.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Related articles  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/uk.investing.com\/news\/stock-market-news\/hsbc-lifts-novartis-downgrades-amgen-in-biopharma-catalyst-review-4863850?utm_medium=feed&amp;utm_source=yahoo&amp;utm_campaign=yahoo-uk\" data-ylk=\"slk:HSBC%20lifts%20Novartis%2C%20downgrades%20Amgen%20in%20biopharma%20catalyst%20review;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/uk.investing.com\/news\/stock-market-news\/european-equities-stabilize-from-selloff-as-traders-brace-for-ecb-decision-4863715?utm_medium=feed&amp;utm_source=yahoo&amp;utm_campaign=yahoo-uk\" data-ylk=\"slk:European%20equities%20stabilize%20from%20sell-off%20as%20traders%20brace%20for%20ECB%20decision;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;European equities stabilize from sell-off as traders brace for ECB decision&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">European equities stabilize from sell-off as traders brace for ECB decision<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/uk.investing.com\/news\/stock-market-news\/openai-restricts-rival-ai-ad-campaigns-in-chatgpt-as-competition-heats-up--report-4863364?utm_medium=feed&amp;utm_source=yahoo&amp;utm_campaign=yahoo-uk\" data-ylk=\"slk:OpenAI%20restricts%20rival%20AI%20ad%20campaigns%20in%20ChatGPT%20as%20competition%20heats%20up%20-%20report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;OpenAI restricts rival AI ad campaigns in ChatGPT as competition heats up - report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">OpenAI restricts rival AI ad campaigns in ChatGPT as competition heats up &#8211; report<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"Investing.com &#8212; HSBC adjusted ratings and target prices across its biopharma coverage, citing &#8220;a lower sector additional risk&hellip;\n","protected":false},"author":2,"featured_media":135994,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[2847,206,65598,65599],"class_list":["post-135993","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-hsbc","tag-novartis","tag-rajesh-kumar","tag-target-prices"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117329241227777031","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/135993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=135993"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/135993\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/135994"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=135993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=135993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=135993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}